What is Verastem, Inc. (VSTM)?

Verastem, Inc. (VSTM) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of VSTM?

The current price of VSTM is $9.66. Prices are updated in real time on Stocks360.

What is VSTM's price-to-earnings (PE) ratio?

VSTM's trailing twelve-month PE ratio is -3.93, based on current price and earnings per share data available on Stocks360.

What is VSTM's market capitalization?

VSTM's market capitalization is $874,842,840.00, placing it in the small-cap tier.

Verastem, Inc. (VSTM)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.66

Market Cap

$874.84M

PE (TTM)

-3.93

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.32

Day Range

$9.54 – $10.03

52-wk Range

$3.43 – $10.82

Avg Volume

N/A

Volume

1.94M

Verastem, Inc. (VSTM) is a publicly traded company in the Healthcare sector. Latest price: $9.66. Market cap $874.84M. Trailing PE -3.93. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $9.23 2026-10-29 · $9.66 (+4.66%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.35 vs est. $-0.43

Beat by $0.08

Next Earnings

Nov 5, 2026

EPS estimate $-0.44

Proprietary Signals

Signal snapshot temporarily unavailable.

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strateg…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.93×
P/S (TTM)	10.00×
P/B	19.35×
P/FCF (TTM)	-5.35×
EV / EBITDA	-4.12×
EV / Sales	9.40×
Earnings Yield	-20.96%
Free Cash Flow Yield	-18.69%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$822.82M
Revenue (TTM)	$87.53M
Net Income (TTM)	-$183.36M
Free Cash Flow (TTM)	-$170.34M
Net Debt	-$52.02M
Working Capital	$98.03M
Gross Margin	86.69%
Operating Margin	-182.57%
Net Margin	-231.59%
Return on Equity	-467.49%
Return on Invested Capital	-118.54%